ArticleFrontiers in microbiology2020
Exploring the Bacterial Impact on Cholesterol Cycle: A Numerical Study.
Article in Frontiers in microbiology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed.
- Gut microbiome-blood cholesterol crosstalk: towards personalized strategies for dyslipidemia.Folia microbiologica · 2026Review
- How the Microbiome Drives Cardiovascular Disease.The Surgical clinics of North America · 2025Review
- Weissella confusa MW051433 Mitigates Hypercholesterolemia by Biliary Cholesterol Excretion: The In Vivo Evidence.Current microbiology · 2025Article
- Higher dietary live microbe intake is linked to reduced risk of metabolic syndrome and mortality: a cross-sectional and longitudinal study.Frontiers in nutrition · 2025Article
- Analysis of the Probiotic Potential ofMicroorganisms · 2024Article
- Chronic blue light-emitting diode exposure harvests gut dysbiosis related to cholesterol dysregulation.Frontiers in cellular and infection microbiology · 2023Article
- Diet-gut microbiota interactions on cardiovascular disease.Computational and structural biotechnology journal · 2022Review
- Characterization of microbial communities from gut microbiota of hypercholesterolemic and control subjects.Frontiers in cellular and infection microbiology · 2022Article
- Cholesterol-to-Coprostanol Conversion by the Gut Microbiota: What We Know, Suspect, and Ignore.Microorganisms · 2021Review
- Identification of New Potential Biotherapeutics from Human Gut Microbiota-Derived Bacteria.Microorganisms · 2021Article
- Cholesterol Homeostasis: An In Silico Investigation into How Aging Disrupts Its Key Hepatic Regulatory Mechanisms.Biology · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
High blood cholesterol levels are often associated with cardiovascular diseases. Therapeutic strategies, targeting different functions involved in cholesterol transport or synthesis, were developed to control cholesterolemia in human. However, the gut microbiota is also involved in cholesterol regulation by direct biotransformation of luminal cholesterol or conversion of bile salts, opening the way to the design of new strategies to manage cholesterol level. In this report, we developed for the first time a whole-body human model of cholesterol metabolism including the gut microbiota in order to investigate the relative impact of host and microbial pathways. We first used an animal model to investigate the ingested cholesterol distribution
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.